Jay Flatley
Illumina CEO Jay Flatley has been named a founding board member of Denali Therapeutics, a company developing therapies aimed at neurodegenerative diseases that launched this week with an initial investment commitment of $217 million.
Illumina CEO Jay Flatley has been named a founding board member of Denali Therapeutics, a company developing therapies aimed at neurodegenerative diseases that launched this week with an initial investment commitment of $217 million.